MNG1182
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.469
- IL6_JAK_STAT3_SIGNALING+0.369
- WNT_BETA_CATENIN_SIGNALING+0.369
- PROTEIN_SECRETION+0.333
- MITOTIC_SPINDLE+0.293
- ADIPOGENESIS+0.290
- INTERFERON_GAMMA_RESPONSE+0.265
- PI3K_AKT_MTOR_SIGNALING+0.261
- DNA_REPAIR+0.258
- UV_RESPONSE_DN+0.245
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.263
- PANCREAS_BETA_CELLS-0.186
- KRAS_SIGNALING_DN-0.139
- HEDGEHOG_SIGNALING-0.109
- SPERMATOGENESIS-0.108
- E2F_TARGETS-0.103
- HYPOXIA-0.086
- ESTROGEN_RESPONSE_LATE-0.055
- MTORC1_SIGNALING-0.048
- UV_RESPONSE_UP-0.038
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.469 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.369 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.369 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.333 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.265 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.261 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.258 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.245 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.198 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.193 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.181 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.168 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.167 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.167 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.165 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.161 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.145 | Inavolisib | — uncovered |
| COMPLEMENT | 0.143 | Inavolisib | — uncovered |